Last reviewed · How we verify

Bisacodyl & PEG-CS

Azienda Policlinico Umberto I · FDA-approved active Small molecule ✓ Verified May 2026

Bisacodyl & PEG-CS is a Laxative combination (stimulant + osmotic) Small molecule drug developed by Azienda Policlinico Umberto I. It is currently FDA-approved for Bowel preparation prior to colonoscopy or other gastrointestinal procedures, Constipation management. Also known as: Lovoldyl (Bisacodyl), Lovolesse (PEG-CS), Gastromiro (Iopamidol), Plasil (Metoclopramide mono chlorohydrate monohydrate).

Bisacodyl stimulates colonic muscle contractions while PEG-CS (polyethylene glycol with electrolytes) provides osmotic laxation and bowel cleansing.

Bisacodyl is used in combination with PEG-CS (a solution of polyethylene glycol 4000 added with citrates and simethicone) for bowel preparation, particularly for colonoscopy. This combination is studied for its effectiveness in conditions such as colon polyps, gastrointestinal complications, and colon preparation.

At a glance

Generic nameBisacodyl & PEG-CS
Also known asLovoldyl (Bisacodyl), Lovolesse (PEG-CS), Gastromiro (Iopamidol), Plasil (Metoclopramide mono chlorohydrate monohydrate)
SponsorAzienda Policlinico Umberto I
Drug classLaxative combination (stimulant + osmotic)
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

Bisacodyl is a diphenolic laxative that acts as a contact stimulant, increasing intestinal motility and promoting bowel evacuation. PEG-CS is an osmotic agent that draws water into the intestinal lumen, softening stool and facilitating cleansing. Together, they provide both mechanical stimulation and osmotic hydration for bowel preparation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bisacodyl & PEG-CS

What is Bisacodyl & PEG-CS?

Bisacodyl & PEG-CS is a Laxative combination (stimulant + osmotic) drug developed by Azienda Policlinico Umberto I, indicated for Bowel preparation prior to colonoscopy or other gastrointestinal procedures, Constipation management.

How does Bisacodyl & PEG-CS work?

Bisacodyl stimulates colonic muscle contractions while PEG-CS (polyethylene glycol with electrolytes) provides osmotic laxation and bowel cleansing.

What is Bisacodyl & PEG-CS used for?

Bisacodyl & PEG-CS is indicated for Bowel preparation prior to colonoscopy or other gastrointestinal procedures, Constipation management.

Who makes Bisacodyl & PEG-CS?

Bisacodyl & PEG-CS is developed and marketed by Azienda Policlinico Umberto I (see full Azienda Policlinico Umberto I pipeline at /company/azienda-policlinico-umberto-i).

Is Bisacodyl & PEG-CS also known as anything else?

Bisacodyl & PEG-CS is also known as Lovoldyl (Bisacodyl), Lovolesse (PEG-CS), Gastromiro (Iopamidol), Plasil (Metoclopramide mono chlorohydrate monohydrate).

What drug class is Bisacodyl & PEG-CS in?

Bisacodyl & PEG-CS belongs to the Laxative combination (stimulant + osmotic) class. See all Laxative combination (stimulant + osmotic) drugs at /class/laxative-combination-stimulant-osmotic.

What development phase is Bisacodyl & PEG-CS in?

Bisacodyl & PEG-CS is FDA-approved (marketed).

What are the side effects of Bisacodyl & PEG-CS?

Common side effects of Bisacodyl & PEG-CS include Abdominal cramping, Nausea, Diarrhea, Electrolyte imbalance.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing